TABLE 1.

Virologic Outcomes at Week 48

			E/C/F/TAF vs ATV + RTV plus FTC/TDF
	E/C/F/TAF (n = 159)	ATV+RTV plus FTC/TDF (n = 53)	P	Difference in Percentages (95% CI)†
HIV-1 RNA <50 copies/mL†	150 (94%)	46 (87%)	0.13	7.5% (21.2% to 19.4%)
HIV-1 RNA ≥50 copies/mL	3 (2%)	2 (4%)
HIV-1 RNA ≥50 copies/mL	2 (1%)	2 (4%)
Discontinued because of the lack of efficacy	0	0
Discontinued because of other reasons and the last available HIV-1 RNA ≥50 copies/ mL*	1 (1%)	0
Added new ARV	0	0
No virologic data	6 (4%)	5 (9%)
Discontinued because of AE/death	1 (1%)	1 (2%)
Discontinued because of other reasons* and the last available HIV-1 RNA <50 copies/ mL	4 (3%)	3 (6%)
Missing data but on study drug	1 (1%)	1 (2%)
HIV-1 RNA <50 copies/mL by missing = failure‡	150 (94%)	47 (89%)	0.21	5.7% (22.5% to 17.2%)
HIV-1 RNA <50 copies/mL by missing = excluded‡	150/153 (98%)	47/49 (96%)	0.60	2.1% (22.9% to 11.4%)

Data are n (%).

^*Other reasons include subjects who discontinued study drug because of investigator’s discretion, withdrawal of consent, lost to follow-up, noncompliance with study drug, protocol violation, and pregnancy.

^†P values were from the Fisher exact test. Difference in percentages of virologic success and its 95% CI were calculated based on exact method. The exact CI was estimated based on an unconditional exact method using 2 inverted 1-sided tests with the standardized statistic.

^‡P value, difference in percentages, and 95% CI were based on a dichotomized response: success (HIV-1 RNA <50 copies/mL) or failure (HIV-1 RNA ≥50 copies/mL or missing) for missing = failure approach or missing = excluded approach. Difference in percentage of virologic success and its 95% CI were calculated based on an unconditional exact method using 2 inverted one-sided tests with the standardized statistic.